Research and Treatment

Research & Treatment

The most common inherited bleeding disorder, von Willebrand disease (VWD) has also been one of the most difficult to diagnose...
Two subcutaneous therapies are currently being investigated.
MLOF is open to all people with hemophilia A and B.
More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.
The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.
Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.
An update on FVII gene therapy and more.
Telemedicine can bridge the distance between doctor and patients.
Updates on Daklinza, Technivie, and the ACE910 trial
NHF is committed to the training and support of clinician-researchers in hematology.
NHF awarded 5 JGP Fellowships in 2014.
There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval...
Chat Icon
Need Info? Ask NHF!
Contact HANDI, NHF's resource center for additional information on bleeding disorders.